H-1023.1	

HOUSE BILL 1769

55th Legislature

1998 Regular Session

By Representatives Zellinsky, Sheldon and L. Thomas

Read first time 02/07/97. Referred to Committee on Health Care.

- 1 AN ACT Relating to electronic transfer of prescription information;
- 2 amending RCW 69.41.010 and 69.50.101; adding a new section to chapter
- 3 69.41 RCW; and adding a new section to chapter 69.50 RCW.
- 4 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF WASHINGTON:
- 5 **Sec. 1.** RCW 69.41.010 and 1996 c 178 s 16 are each amended to read 6 as follows:
- As used in this chapter, the following terms have the meanings indicated unless the context clearly requires otherwise:
- 9 (1) "Administer" means the direct application of a legend drug 10 whether by injection, inhalation, ingestion, or any other means, to the
- 11 body of a patient or research subject by:
- 12 (a) A practitioner; or

State of Washington

- 13 (b) The patient or research subject at the direction of the 14 practitioner.
- 15 (2) "Deliver" or "delivery" means the actual, constructive, or
- 16 attempted transfer from one person to another of a legend drug, whether
- 17 or not there is an agency relationship.
- 18 (3) "Department" means the department of health.

p. 1 HB 1769

- 1 (4) "Dispense" means the interpretation of a prescription or order 2 for a legend drug and, pursuant to that prescription or order, the 3 proper selection, measuring, compounding, labeling, or packaging 4 necessary to prepare that prescription or order for delivery.
 - (5) "Dispenser" means a practitioner who dispenses.
- 6 (6) "Distribute" means to deliver other than by administering or dispensing a legend drug.
 - (7) "Distributor" means a person who distributes.
 - (8) "Drug" means:

5

8

9

- 10 (a) Substances recognized as drugs in the official United States
 11 pharmacopoeia, official homeopathic pharmacopoeia of the United States,
 12 or official national formulary, or any supplement to any of them;
- (b) Substances intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or animals;
- 15 (c) Substances (other than food, minerals or vitamins) intended to 16 affect the structure or any function of the body of man or animals; and
- (d) Substances intended for use as a component of any article specified in clause (a), (b), or (c) of this subsection. It does not include devices or their components, parts, or accessories.
- (9) "Electronic communication of prescription information" means
 the communication of prescription information by computer, or the
 transmission of an exact visual image of a prescription by facsimile,
 or other electronic means for original prescription information or
 prescription refill information for a legend drug from an authorized
 practitioner to a pharmacy or the transfer of prescription information
 for a legend drug from one pharmacy to another pharmacy.
- 27 (10) "Legend drugs" means any drugs which are required by state law 28 or regulation of the state board of pharmacy to be dispensed on 29 prescription only or are restricted to use by practitioners only.
- 30 (((10))) <u>(11)</u> "Person" means individual, corporation, government or 31 governmental subdivision or agency, business trust, estate, trust, 32 partnership or association, or any other legal entity.
- 33 $\left(\left(\frac{(11)}{(12)}\right)\right)$ "Practitioner" means:
- 34 (a) A physician under chapter 18.71 RCW, an osteopathic physician 35 or an osteopathic physician and surgeon under chapter 18.57 RCW, a 36 dentist under chapter 18.32 RCW, a podiatric physician and surgeon 37 under chapter 18.22 RCW, a veterinarian under chapter 18.92 RCW, a 38 registered nurse, advanced registered nurse practitioner, or licensed 39 practical nurse under chapter 18.79 RCW, an optometrist under chapter

нв 1769 р. 2

- 1 18.53 RCW who is certified by the optometry board under RCW 18.53.010,
- 2 an osteopathic physician assistant under chapter 18.57A RCW, a
- 3 physician assistant under chapter 18.71A RCW, or a pharmacist under
- 4 chapter 18.64 RCW;
- 5 (b) A pharmacy, hospital, or other institution licensed,
- 6 registered, or otherwise permitted to distribute, dispense, conduct
- 7 research with respect to, or to administer a legend drug in the course
- 8 of professional practice or research in this state; and
- 9 (c) A physician licensed to practice medicine and surgery or a
- 10 physician licensed to practice osteopathic medicine and surgery in any
- 11 state, or province of Canada, which shares a common border with the
- 12 state of Washington.
- 13 $((\frac{12}{12}))$ "Secretary" means the secretary of health or the
- 14 secretary's designee.
- 15 <u>NEW SECTION.</u> **Sec. 2.** A new section is added to chapter 69.41 RCW
- 16 to read as follows:
- 17 (1) Information concerning an original prescription or information
- 18 concerning a prescription refill for a legend drug may be
- 19 electronically communicated to a pharmacy of the patient's choice
- 20 pursuant to the provisions of this chapter if the electronically
- 21 communicated prescription information complies with the following:
- 22 (a) Electronically communicated prescription information must
- 23 comply with all applicable statutes and rules regarding the form,
- 24 content, recordkeeping, and processing of a prescription for a legend
- 25 drug; and
- 26 (b) The system used for transmitting electronically communicated
- 27 prescription information and the system used for receiving
- 28 electronically communicated prescription information must be approved
- 29 by the board. This subsection does not apply to currently used
- 30 facsimile equipment transmitting an exact visual image of the
- 31 prescription. The board shall maintain and provide, upon request, a
- 32 list of systems used for electronically communicating prescription
- 33 information currently approved by the board.
- 34 (2) The board may adopt rules implementing this section.
- 35 **Sec. 3.** RCW 69.50.101 and 1996 c 178 s 18 are each amended to read
- 36 as follows:

p. 3 HB 1769

- Unless the context clearly requires otherwise, definitions of terms shall be as indicated where used in this chapter:
- 3 (a) "Administer" means to apply a controlled substance, whether by 4 injection, inhalation, ingestion, or any other means, directly to the 5 body of a patient or research subject by:
- 6 (1) a practitioner authorized to prescribe (or, by the 7 practitioner's authorized agent); or
- 8 (2) the patient or research subject at the direction and in the 9 presence of the practitioner.
- (b) "Agent" means an authorized person who acts on behalf of or at the direction of a manufacturer, distributor, or dispenser. It does not include a common or contract carrier, public warehouseperson, or employee of the carrier or warehouseperson.
- 14 (c) "Board" means the state board of pharmacy.
- 15 (d) "Controlled substance" means a drug, substance, or immediate 16 precursor included in Schedules I through V as set forth in federal or 17 state laws, or federal or board rules.
- (e)(1) "Controlled substance analog" means a substance the chemical structure of which is substantially similar to the chemical structure of a controlled substance in Schedule I or II and:
- (i) that has a stimulant, depressant, or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled substance included in Schedule I or II; or
- (ii) with respect to a particular individual, that the individual represents or intends to have a stimulant, depressant, or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled substance included in Schedule I or II.
- 31 (2) The term does not include:
- 32 (i) a controlled substance;
- 33 (ii) a substance for which there is an approved new drug 34 application;
- (iii) a substance with respect to which an exemption is in effect for investigational use by a particular person under Section 505 of the federal Food, Drug and Cosmetic Act, 21 U.S.C. Sec. 355, to the extent conduct with respect to the substance is pursuant to the exemption; or

HB 1769 p. 4

- 1 (iv) any substance to the extent not intended for human consumption 2 before an exemption takes effect with respect to the substance.
- 3 (f) "Deliver" or "delivery," means the actual or constructive 4 transfer from one person to another of a substance, whether or not 5 there is an agency relationship.
 - (g) "Department" means the department of health.

6

11

14

29

- 7 (h) "Dispense" means the interpretation of a prescription or order 8 for a controlled substance and, pursuant to that prescription or order, 9 the proper selection, measuring, compounding, labeling, or packaging 10 necessary to prepare that prescription or order for delivery.
 - (i) "Dispenser" means a practitioner who dispenses.
- 12 (j) "Distribute" means to deliver other than by administering or 13 dispensing a controlled substance.
 - (k) "Distributor" means a person who distributes.
- (1) "Drug" means (1) a controlled substance recognized as a drug in 15 the official United States pharmacopoeia/national formulary or the 16 17 official homeopathic pharmacopoeia of the United States, or any supplement to them; (2) controlled substances intended for use in the 18 19 diagnosis, cure, mitigation, treatment, or prevention of disease in 20 individuals or animals; (3) controlled substances (other than food) intended to affect the structure or any function of the body of 21 individuals or animals; and (4) controlled substances intended for use 22 23 as a component of any article specified in (1), (2), or (3) of this 24 subsection. The term does not include devices or their components, 25 parts, or accessories.
- 26 (m) "Drug enforcement administration" means the drug enforcement 27 administration in the United States Department of Justice, or its 28 successor agency.
 - (n) "Immediate precursor" means a substance:
- 30 (1) that the state board of pharmacy has found to be and by rule 31 designates as being the principal compound commonly used, or produced 32 primarily for use, in the manufacture of a controlled substance;
- 33 (2) that is an immediate chemical intermediary used or likely to be 34 used in the manufacture of a controlled substance; and
- 35 (3) the control of which is necessary to prevent, curtail, or limit 36 the manufacture of the controlled substance.
- 37 (o) "Isomer" means an optical isomer, but in RCW 69.50.101(r)(5), 38 69.50.204(a) (12) and (34), and 69.50.206(a)(4), the term includes any 39 geometrical isomer; in RCW 69.50.204(a) (8) and (42), and 69.50.210(c)

p. 5 HB 1769

- the term includes any positional isomer; and in RCW 69.50.204(a)(35), 1 69.50.204(c), and 69.50.208(a) the term includes any positional or 2 3 geometric isomer.
- 4 (p) "Manufacture" means the production, preparation, propagation, 5 compounding, conversion, or processing of a controlled substance, either directly or indirectly or by extraction from substances of 6 natural origin, or independently by means of chemical synthesis, or by 7 8 a combination of extraction and chemical synthesis, and includes any packaging or repackaging of the substance or labeling or relabeling of 9 its container. The term does not include the preparation, compounding, 10 packaging, repackaging, labeling, or relabeling of a controlled 11 12 substance:
- 13 (1) by a practitioner as an incident to the practitioner's administering or dispensing of a controlled substance in the course of 14 15 the practitioner's professional practice; or
- 16 (2) by a practitioner, or by the practitioner's authorized agent 17 under the practitioner's supervision, for the purpose of, or as an incident to, research, teaching, or chemical analysis and not for sale. 18
- 19 (q) "Marijuana" or "marihuana" means all parts of the plant 20 Cannabis, whether growing or not; the seeds thereof; the resin extracted from any part of the plant; and every compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seeds or 22 23 resin. The term does not include the mature stalks of the plant, fiber 24 produced from the stalks, oil or cake made from the seeds of the plant, any other compound, manufacture, salt, derivative, mixture, 26 preparation of the mature stalks (except the resin extracted 27 therefrom), fiber, oil, or cake, or the sterilized seed of the plant which is incapable of germination. 28
- 29 (r) "Narcotic drug" means any of the following, whether produced 30 directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a 31 combination of extraction and chemical synthesis: 32
- 33 (1) Opium, opium derivative, and any derivative of opium or opium 34 derivative, including their salts, isomers, and salts of isomers, 35 whenever the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation. The term does not 36 37 include the isoquinoline alkaloids of opium.
- (2) Synthetic opiate and any derivative of synthetic opiate, 38 39 including their isomers, esters, ethers, salts, and salts of isomers,

HB 1769 p. 6

21

25

- 1 esters, and ethers, whenever the existence of the isomers, esters, 2 ethers, and salts is possible within the specific chemical designation.
- 3 (3) Poppy straw and concentrate of poppy straw.
- 4 (4) Coca leaves, except coca leaves and extracts of coca leaves 5 from which cocaine, ecgonine, and derivatives or ecgonine or their 6 salts have been removed.
- 7 (5) Cocaine, or any salt, isomer, or salt of isomer thereof.
- 8 (6) Cocaine base.
- 9 (7) Ecgonine, or any derivative, salt, isomer, or salt of isomer 10 thereof.
- 11 (8) Any compound, mixture, or preparation containing any quantity 12 of any substance referred to in subparagraphs (1) through (7).
- 13 (s) "Opiate" means any substance having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of 14 15 conversion into a drug having addiction-forming or addiction-sustaining 16 The term includes opium, substances derived from opium 17 (opium derivatives), and synthetic opiates. The term does not include, unless specifically designated as controlled under RCW 69.50.201, the 18 19 dextrorotatory isomer of 3-methoxy-n-methylmorphinan and its salts 20 (dextromethorphan). The term includes the racemic and levorotatory 21 forms of dextromethorphan.
- (t) "Opium poppy" means the plant of the species Papaver somniferum
 L., except its seeds.
- (u) "Person" means individual, corporation, business trust, estate, trust, partnership, association, joint venture, government, governmental subdivision or agency, or any other legal or commercial entity.
- (v) "Poppy straw" means all parts, except the seeds, of the opium poppy, after mowing.
- 30 (w) "Practitioner" means:
- (1) A physician under chapter 18.71 RCW, a physician assistant 31 under chapter 18.71A RCW, an osteopathic physician and surgeon under 32 33 chapter 18.57 RCW, a dentist under chapter 18.32 RCW, a podiatric physician and surgeon under chapter 18.22 RCW, a veterinarian under 34 35 chapter 18.92 RCW, a registered nurse, advanced registered nurse practitioner, or licensed practical nurse under chapter 18.79 RCW, a 36 37 pharmacist under chapter 18.64 RCW or a scientific investigator under this chapter, licensed, registered or otherwise permitted insofar as is 38 39 consistent with those licensing laws to distribute, dispense, conduct

p. 7 HB 1769

- research with respect to or administer a controlled substance in the course of their professional practice or research in this state.
- (2) A pharmacy, hospital or other institution licensed, registered, or otherwise permitted to distribute, dispense, conduct research with respect to or to administer a controlled substance in the course of professional practice or research in this state.
- (3) A physician licensed to practice medicine and surgery, a physician licensed to practice osteopathic medicine and surgery, a dentist licensed to practice dentistry, a podiatric physician and surgeon licensed to practice podiatric medicine and surgery, or a veterinarian licensed to practice veterinary medicine in any state of the United States.
- (x) "Prescription" means an order for controlled substances issued 13 by a practitioner duly authorized by law or rule in the state of 14 15 Washington to prescribe controlled substances within the scope of his or her professional practice for a legitimate medical purpose. 16
- 17 (y) "Production" includes the manufacturing, planting, cultivating, growing, or harvesting of a controlled substance. 18
- 19 (z) "Secretary" means the secretary of health or the secretary's 20 designee.
- (aa) "State," unless the context otherwise requires, means a state 21 of the United States, the District of Columbia, the Commonwealth of 22 23 Puerto Rico, or a territory or insular possession subject to the 24 jurisdiction of the United States.
- 25 (bb) "Ultimate user" means an individual who lawfully possesses a controlled substance for the individual's own use or for the use of a 26 27 member of the individual's household or for administering to an animal owned by the individual or by a member of the individual's household. 28
- 29 (cc) "Electronic communication of prescription information" means 30 the communication of prescription information by computer, or the 31 transmission of an exact visual image of a prescription by facsimile, or other electronic means for original prescription information or 32 prescription refill information for a controlled substance from an 33
- 34 authorized practitioner to a pharmacy or the transfer of prescription
- 35 information for a controlled substance from one pharmacy to another
- 36 pharmacy.

1 2

3

4 5

6 7

8

9

10

11

12

37 NEW SECTION. Sec. 4. A new section is added to chapter 69.50 RCW

to read as follows: 38

> HB 1769 p. 8

(1) Information concerning an original prescription or information concerning a prescription refill for a controlled substance may be electronically communicated to a pharmacy of the patient's choice pursuant to the provisions of this chapter if the electronically communicated prescription information complies with the following:

1

2

4

5

6 7

8

9

- (a) Electronically communicated prescription information must comply with all applicable statutes and rules regarding the form, content, recordkeeping, and processing of a prescription for a legend drug; and
- 10 (b) The system used for transmitting electronically communicated prescription information and the system used for receiving 11 electronically communicated prescription information must be approved 12 This subsection does not apply to currently used 13 by the board. facsimile equipment transmitting an exact visual image of the 14 15 prescription. The board shall maintain and provide, upon request, a list of systems used for electronically communicating prescription 16 17 information currently approved by the board.
- 18 (2) The board may adopt rules implementing this section.

--- END ---

p. 9 HB 1769